A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors

NCT05978102 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

183

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: STI-7349
DRUG: Pembrolizumab
DRUG: Standard treatment（SoC）
DRUG: approved PD-1/PD-L1 inhibitors (e.g., Tislelizumab, etc.)

Sponsor

The Fourth Affiliated Hospital of Zhejiang University School of Medicine